التفاصيل البيبلوغرافية
| العنوان: |
DataSheet_1_Ultra-rapid Idylla™ EGFR mutation screening followed by next-generation sequencing: An integrated solution to molecular diagnosis of non-small cell lung cancer.docx |
| المؤلفون: |
Tian Qiu, Fanshuang Zhang, Bo Zheng, Zitong Feng, Weihua Li, Hua Zeng, Lixia Chu, Jianming Ying |
| سنة النشر: |
2023 |
| المجموعة: |
Frontiers: Figshare |
| مصطلحات موضوعية: |
Cancer, Cancer Cell Biology, Cancer Diagnosis, Cancer Genetics, Cancer Therapy (excl. Chemotherapy and Radiation Therapy), Chemotherapy, Haematological Tumours, Molecular Targets, Radiation Therapy, Solid Tumours, Oncology and Carcinogenesis not elsewhere classified, rapid detection, epidermal growth factor receptor, IdyllaTMEGFR assay, Chinese NSCLC patients, molecular diagnosis |
| الوصف: |
Background Rapid profiling of the EGFR mutations is crucial to help clinicians choose the optimal treatment for patients with advanced/metastatic Non-Small Cell Lung Cancer (NSCLC). Unfortunately, current diagnostic techniques, including ARMS-PCR and NGS, generally require several days to deliver final results. This diagnostic delay may lead to treatment delays for patients who are worsening rapidly. Methods This study introduced the ultra-rapid Idylla™ system for rapid, sensitive and specific identification of the EGFR mutations among Chinese NSCLC patients. Idylla™ EGFR Assay, an integrated cartridge running on the Idylla™ system, which can detect 51 EGFR mutations directly from Formalin-Fixed, Paraffin-Embedded (FFPE) samples within 2.5 hours, was used in this study. The sensitivity and specificity of the Idylla™ system were evaluated in comparison with ARMS-PCR or NGS using 95 clinical samples. Results The Idylla™ system achieved a sensitivity of 97.6%, a specificity of 100%, and an overall concordance of 97.9% for 95 retrospective samples. When compared to ARMS-PCR, the Idylla™ system demonstrated high accuracy with an overall agreement of 97.1% (34/35), a sensitivity of 95.2% (20/21) (95% CI, 76.2% - 99.9%), and an estimated specificity of 100% (12/12) (95% CI, 76.8% - 100%) for 35 prospective samples. Conclusions This Idylla system provides a rapid, accurate and simple approach for screening EGFR mutations, which can guide Tyrosine Kinase Inhibitors (TKI) treatment for NSCLC patients in a timely manner. |
| نوع الوثيقة: |
dataset |
| اللغة: |
unknown |
| Relation: |
https://figshare.com/articles/dataset/DataSheet_1_Ultra-rapid_Idylla_EGFR_mutation_screening_followed_by_next-generation_sequencing_An_integrated_solution_to_molecular_diagnosis_of_non-small_cell_lung_cancer_docx/22428712 |
| DOI: |
10.3389/fonc.2023.1064487.s001 |
| الاتاحة: |
https://doi.org/10.3389/fonc.2023.1064487.s001
https://figshare.com/articles/dataset/DataSheet_1_Ultra-rapid_Idylla_EGFR_mutation_screening_followed_by_next-generation_sequencing_An_integrated_solution_to_molecular_diagnosis_of_non-small_cell_lung_cancer_docx/22428712 |
| Rights: |
CC BY 4.0 |
| رقم الانضمام: |
edsbas.3915742F |
| قاعدة البيانات: |
BASE |